Related Links
- MASH and Hepatic Fibrosis: Intersecting Metabolic Pathways
- How to Manage PMI? – Practical Implementation in Ramathibodi Hospital
- Lp(a) Screening at Least Once a Lifetime! Unwrapping the What, Why and How’s of Lipoprotein(a)
- NT-proBNP as a predictor of Cardio-renal Complications in PwD
- Safety of Rx Optimisation Post AHF Hospitalization
- Practical Implementation of GDMT Optimisation – The ATP in NZ
- Use of Rapid Algo for Suspected AMI – Faster Triage of ED Patients
- Navigating Cardiotoxicity – Value of Cardiac Biomarkers
- DROP Asian ACS – Study Results and Practical Approach
- The Importance of Early Diagnosis and Management of AHF
- Integrative Approaches to Managing Diabetes and Cardiovascular Disease
- Optimising GDMT Post AHF Discharge – APAC APSC Consensus Highlights
- Initiation of GDMT Therapy in Patients Discharged Post AHF – What are the Guardrails?
- Enhancing Diabetes and Cardiovascular Management with Continuous Glucose Monitoring
- New Frontiers for Risk Stratification Assays for Acute Coronary Syndrome – The Gen6 Assay for hs cTnT
- NT-proBNP for Rapid Optimisation of GDMT in AHF Patients in Japan
- STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management
- NT-proBNP and ECHO in heart failure – do they always go hand in hand?
- Rapid ACS Rule Out in Emergency Patients
- How to Implement the 0-h/1-h Algorithm to your Institute?
- High Sensitivity Cardiac Troponins and ACS – the Malaysian Experience
- APAC Heart Failure Gap Report
- Value of NT-ProBNP for Treatment Monitoring in CHF